Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Fundamental Analysis

NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD

0.754  -0.02 (-2.09%)

After market: 0.754 0 (0%)

Fundamental Rating

2

RLYB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. RLYB has a great financial health rating, but its profitability evaluates not so good. RLYB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RLYB has reported negative net income.
In the past year RLYB has reported a negative cash flow from operations.
In the past 5 years RLYB always reported negative net income.
RLYB had a negative operating cash flow in each of the past 5 years.
RLYB Yearly Net Income VS EBIT VS OCF VS FCFRLYB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -84.77%, RLYB is doing worse than 70.69% of the companies in the same industry.
RLYB's Return On Equity of -94.57% is in line compared to the rest of the industry. RLYB outperforms 47.07% of its industry peers.
Industry RankSector Rank
ROA -84.77%
ROE -94.57%
ROIC N/A
ROA(3y)-42.41%
ROA(5y)-45.43%
ROE(3y)-45.45%
ROE(5y)-51.94%
ROIC(3y)N/A
ROIC(5y)N/A
RLYB Yearly ROA, ROE, ROICRLYB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

RLYB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLYB Yearly Profit, Operating, Gross MarginsRLYB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for RLYB remains at a similar level compared to 1 year ago.
RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLYB Yearly Shares OutstandingRLYB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
RLYB Yearly Total Debt VS Total AssetsRLYB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.51, we must say that RLYB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.51, RLYB is doing worse than 60.04% of the companies in the same industry.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.51
ROIC/WACCN/A
WACCN/A
RLYB Yearly LT Debt VS Equity VS FCFRLYB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.55 indicates that RLYB has no problem at all paying its short term obligations.
RLYB has a better Current ratio (9.55) than 79.04% of its industry peers.
RLYB has a Quick Ratio of 9.55. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 9.55, RLYB is doing good in the industry, outperforming 79.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.55
Quick Ratio 9.55
RLYB Yearly Current Assets VS Current LiabilitesRLYB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

RLYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 1.44% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.3%
EPS Next 2Y12.58%
EPS Next 3Y-2.47%
EPS Next 5Y1.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLYB Yearly Revenue VS EstimatesRLYB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
RLYB Yearly EPS VS EstimatesRLYB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLYB. In the last year negative earnings were reported.
Also next year RLYB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLYB Price Earnings VS Forward Price EarningsRLYB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLYB Per share dataRLYB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

RLYB's earnings are expected to decrease with -2.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.58%
EPS Next 3Y-2.47%

More info and screens

0

5. Dividend

5.1 Amount

RLYB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RALLYBIO CORP

NASDAQ:RLYB (2/21/2025, 8:00:01 PM)

After market: 0.754 0 (0%)

0.754

-0.02 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-18 2025-03-18/amc
Inst Owners69.98%
Inst Owner Change1.21%
Ins Owners2.32%
Ins Owner Change0%
Market Cap31.28M
Analysts81.82
Price Target8.41 (1015.38%)
Short Float %0.95%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.34%
Min EPS beat(2)3.01%
Max EPS beat(2)27.67%
EPS beat(4)3
Avg EPS beat(4)6.1%
Min EPS beat(4)-9.05%
Max EPS beat(4)27.67%
EPS beat(8)7
Avg EPS beat(8)10.1%
EPS beat(12)8
Avg EPS beat(12)5.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.43%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)10.28%
EPS NY rev (1m)0%
EPS NY rev (3m)7.06%
Revenue NQ rev (1m)-25%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)181.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.31
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.01
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.77%
ROE -94.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.41%
ROA(5y)-45.43%
ROE(3y)-45.45%
ROE(5y)-51.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.55
Quick Ratio 9.55
Altman-Z -4.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.47%
Cap/Depr(5y)240.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
EPS Next Y21.3%
EPS Next 2Y12.58%
EPS Next 3Y-2.47%
EPS Next 5Y1.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.32%
EBIT Next 3Y12.42%
EBIT Next 5YN/A
FCF growth 1Y1.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.61%
OCF growth 3YN/A
OCF growth 5YN/A